{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:54:08Z","timestamp":1789016048720,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01669-0","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T07:41:33Z","timestamp":1745912493000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["m6A hypermethylation of TCF-1 regulated by METTL16 promotes acute myeloid leukemia"],"prefix":"10.1007","volume":"25","author":[{"given":"Jingyi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"key":"1669_CR1","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41408-021-00503-6","volume":"11","author":"G Borthakur","year":"2021","unstructured":"Borthakur G, Kantarjian H. Core binding factor acute myelogenous leukemia-2021 treatment algorithm. Blood Cancer J. 2021;11:114.","journal-title":"Blood Cancer J"},{"key":"1669_CR2","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1182\/blood-2019-01-894980","volume":"133","author":"MA Sanz","year":"2019","unstructured":"Sanz MA, Fenaux P, Tallman MS, Estey EH, Lowenberg B, Naoe T, Lengfelder E, Dohner H, Burnett AK, Chen SJ, Mathews V, Iland H, Rego E, Kantarjian H, Ades L, Avvisati G, Montesinos P, Platzbecker U, Ravandi F, Russell NH, Lo-Coco F. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019;133:1630\u201343.","journal-title":"Blood"},{"key":"1669_CR3","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","volume":"131","author":"GJ Schuurhuis","year":"2018","unstructured":"Schuurhuis GJ, Heuser M, Freeman S, Bene MC, Buccisano F, Cloos J, Grimwade D, Haferlach T, Hills RK, Hourigan CS, Jorgensen JL, Kern W, Lacombe F, Maurillo L, Preudhomme C, van der Reijden BA, Thiede C, Venditti A, Vyas P, Wood BL, Walter RB, Dohner K, Roboz GJ, Ossenkoppele GJ. Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD working party. Blood. 2018;131:1275\u201391.","journal-title":"Blood"},{"issue":"2023","key":"1669_CR4","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1002\/ajh.26984","volume":"98","author":"G Garcia-Manero","year":"2023","unstructured":"Garcia-Manero G. Myelodysplastic syndromes update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98(2023):1307\u201325.","journal-title":"Am J Hematol"},{"key":"1669_CR5","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. \u201cOff-the-shelf\u201d allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19:185\u201399.","journal-title":"Nat Rev Drug Discov"},{"key":"1669_CR6","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20:359\u201371.","journal-title":"Nat Rev Clin Oncol"},{"key":"1669_CR7","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","volume":"173","author":"MY Kim","year":"2018","unstructured":"Kim MY, Yu KR, Kenderian SS, Ruella M, Chen S, Shin TH, Aljanahi AA, Schreeder D, Klichinsky M, Shestova O, Kozlowski MS, Cummins KD, Shan X, Shestov M, Bagg A, Morrissette JJD, Sekhri P, Lazzarotto CR, Calvo KR, Kuhns DB, Donahue RE, Behbehani GK, Tsai SQ, Dunbar CE, Gill S. Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. Cell. 2018;173:1439-1453 e1419.","journal-title":"Cell"},{"key":"1669_CR8","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","volume":"41","author":"K Pan","year":"2022","unstructured":"Pan K, Farrukh H, Chittepu V, Xu H, Pan CX, Zhu Z. CAR race to cancer immunotherapy: from CAR T CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res. 2022;41:119.","journal-title":"J Exp Clin Cancer Res"},{"key":"1669_CR9","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1016\/j.cell.2023.06.002","volume":"186","author":"L Ma","year":"2023","unstructured":"Ma L, Hostetler A, Morgan DM, Maiorino L, Sulkaj I, Whittaker CA, Neeser A, Pires IS, Yousefpour P, Gregory J, Qureshi K, Dye J, Abraham W, Suh H, Li N, Love JC, Irvine DJ. Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. Cell. 2023;186:3148-3165 e3120.","journal-title":"Cell"},{"key":"1669_CR10","doi-asserted-by":"publisher","first-page":"7239","DOI":"10.1093\/nar\/gkab378","volume":"49","author":"S Oerum","year":"2021","unstructured":"Oerum S, Meynier V, Catala M, Tisne C. A comprehensive review of m6A\/m6Am RNA methyltransferase structures. Nucleic Acids Res. 2021;49:7239\u201355.","journal-title":"Nucleic Acids Res"},{"key":"1669_CR11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41392-020-00450-x","volume":"6","author":"X Jiang","year":"2021","unstructured":"Jiang X, Liu B, Nie Z, Duan L, Xiong Q, Jin Z, Yang C, Chen Y. The role of m6A modification in the biological functions and diseases. Signal Transduct Target Ther. 2021;6:74.","journal-title":"Signal Transduct Target Ther"},{"key":"1669_CR12","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12943-020-01204-7","volume":"19","author":"T Wang","year":"2020","unstructured":"Wang T, Kong S, Tao M, Ju S. The potential role of RNA N6-methyladenosine in cancer progression. Mol Cancer. 2020;19:88.","journal-title":"Mol Cancer"},{"key":"1669_CR13","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12943-022-01620-x","volume":"21","author":"H Lin","year":"2022","unstructured":"Lin H, Wang Y, Wang P, Long F, Wang T. Mutual regulation between N6-methyladenosine (m6A) modification and circular RNAs in cancer: impacts on therapeutic resistance. Mol Cancer. 2022;21:148.","journal-title":"Mol Cancer"},{"key":"1669_CR14","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.1038\/s41388-020-1303-7","volume":"39","author":"C Zhang","year":"2020","unstructured":"Zhang C, Huang S, Zhuang H, Ruan S, Zhou Z, Huang K, Ji F, Ma Z, Hou B, He X. YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation. Oncogene. 2020;39:4507\u201318.","journal-title":"Oncogene"},{"key":"1669_CR15","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.stem.2022.12.006","volume":"30","author":"L Han","year":"2023","unstructured":"Han L, Dong L, Leung K, Zhao Z, Li Y, Gao L, Chen Z, Xue J, Qing Y, Li W, Pokharel SP, Gao M, Chen M, Shen C, Tan B, Small A, Wang K, Zhang Z, Qin X, Yang L, Wunderlich M, Zhang B, Mulloy JC, Marcucci G, Chen CW, Wei M, Su R, Chen J, Deng X. METTL16 drives leukemogenesis and leukemia stem cell self-renewal by reprogramming BCAA metabolism. Cell Stem Cell. 2023;30:52\u20136813.","journal-title":"Cell Stem Cell"},{"key":"1669_CR16","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","volume":"19","author":"A Chow","year":"2022","unstructured":"Chow A, Perica K, Klebanoff CA, Wolchok JD. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat Rev Clin Oncol. 2022;19:775\u201390.","journal-title":"Nat Rev Clin Oncol"},{"key":"1669_CR17","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.ccell.2022.06.001","volume":"40","author":"JA Belk","year":"2022","unstructured":"Belk JA, Yao W, Ly N, Freitas KA, Chen YT, Shi Q, Valencia AM, Shifrut E, Kale N, Yost KE, Duffy CV, Daniel B, Hwee MA, Miao Z, Ashworth A, Mackall CL, Marson A, Carnevale J, Vardhana SA, Satpathy AT. Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence. Cancer Cell. 2022;40:768-786.e767.","journal-title":"Cancer Cell"},{"key":"1669_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103941","volume":"77","author":"D Gumber","year":"2022","unstructured":"Gumber D, Wang LD. Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion. EBioMedicine. 2022;77: 103941.","journal-title":"EBioMedicine"},{"key":"1669_CR19","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/s44321-024-00024-2","volume":"16","author":"J Mueller","year":"2024","unstructured":"Mueller J, Schimmer RR, Koch C, Schneiter F, Fullin J, Lysenko V, Pellegrino C, Klemm N, Russkamp N, Myburgh R, Volta L, Theocharides AP, Kurppa KJ, Ebert BL, Schroeder T, Manz MG, Boettcher S. Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells. EMBO Mol Med. 2024;16:445\u201374.","journal-title":"EMBO Mol Med"},{"key":"1669_CR20","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/s41375-023-01905-0","volume":"37","author":"D Nixdorf","year":"2023","unstructured":"Nixdorf D, Sponheimer M, Berghammer D, Engert F, Bader U, Philipp N, Kazerani M, Straub T, Rohrbacher L, Wange L, Dapa S, Atar D, Seitz CM, Brandstetter K, Linder A, von Bergwelt M, Leonhardt H, Mittelstaet J, Kaiser A, Bucklein V, Subklewe M. Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML. Leukemia. 2023;37:1298\u2013310.","journal-title":"Leukemia"},{"key":"1669_CR21","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1038\/s41590-019-0445-7","volume":"20","author":"C Harly","year":"2019","unstructured":"Harly C, Kenney D, Ren G, Lai B, Raabe T, Yang Q, Cam MC, Xue HH, Zhao K, Bhandoola A. The transcription factor TCF-1 enforces commitment to the innate lymphoid cell lineage. Nat Immunol. 2019;20:1150\u201360.","journal-title":"Nat Immunol"},{"key":"1669_CR22","doi-asserted-by":"publisher","first-page":"4512","DOI":"10.1016\/j.cell.2021.07.015","volume":"184","author":"M Di Pilato","year":"2021","unstructured":"Di Pilato M, Kfuri-Rubens R, Pruessmann JN, Ozga AJ, Messemaker M, Cadilha BL, Sivakumar R, Cianciaruso C, Warner RD, Marangoni F, Carrizosa E, Lesch S, Billingsley J, Perez-Ramos D, Zavala F, Rheinbay E, Luster AD, Gerner MY, Kobold S, Pittet MJ, Mempel TR. CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment. Cell. 2021;184:4512\u201345304522.","journal-title":"Cell"},{"key":"1669_CR23","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1182\/blood.2020009309","volume":"138","author":"W Zheng","year":"2021","unstructured":"Zheng W, Wei J, Zebley CC, Jones LL, Dhungana Y, Wang YD, Mavuluri J, Long L, Fan Y, Youngblood B, Chi H, Geiger TL. Regnase-1 suppresses TCF-1+ precursor exhausted T-cell formation to limit CAR-T-cell responses against ALL. Blood. 2021;138:122\u201335.","journal-title":"Blood"},{"key":"1669_CR24","first-page":"309","volume":"8","author":"SA Batra","year":"2020","unstructured":"Batra SA, Rathi P, Guo L, Courtney AN, Fleurence J, Balzeau J, Shaik RS, Nguyen TP, Wu MF, Bulsara S, Mamonkin M, Metelitsa LS, Heczey A. Glypican-3-specific CAR T cells coexpressing IL15 and IL21 have superior expansion and antitumor activity against hepatocellular carcinoma, cancer. Immunol Res. 2020;8:309\u201320.","journal-title":"Immunol Res"},{"key":"1669_CR25","doi-asserted-by":"publisher","first-page":"eadg0878","DOI":"10.1126\/sciimmunol.adg0878","volume":"8","author":"E Humblin","year":"2023","unstructured":"Humblin E, Korpas I, Lu J, Filipescu D, van der Heide V, Goldstein S, Vaidya A, Soares-Schanoski A, Casati B, Selvan ME, Gumus ZH, Wieland A, Corrado M, Cohen-Gould L, Bernstein E, Homann D, Chipuk J, Kamphorst AO. Sustained CD28 costimulation is required for self-renewal and differentiation of TCF-1(+) PD-1(+) CD8 T cells. Sci Immunol. 2023;8:eadg0878.","journal-title":"Sci Immunol"},{"issue":"2","key":"1669_CR26","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1182\/blood.2020009309","volume":"138","author":"W Zheng","year":"2021","unstructured":"Zheng W, Wei J, Zebley CC, et al. Regnase-1 suppresses TCF-1+ precursor exhausted T-cell formation to limit CAR-T-cell responses against ALL. Blood. 2021;138(2):122\u201335.","journal-title":"Blood"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01669-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01669-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01669-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:52:53Z","timestamp":1764917573000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01669-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1669"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01669-0","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,29]]},"assertion":[{"value":"21 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was approved by the Ethics Committee of Shanxi Maternal and Child Health Hospital. The current study was complied with the guidelines outlined in the declaration of Helsinki were followed. The written consent was received from all participants. All animal experiment procedures were performed in accordance with the Guidance Suggestions for the Care and Use of Laboratory Animals, formulated by the Ministry of Science and Technology of China.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"129"}}